Inactive Instrument

Actelion Share Price Other OTC

Equities

Biotechnology & Medical Research

Chart Actelion

Duration

Period

Style

Latest news about Actelion

Actelion : France's Sanofi raises earnings forecast, pleased with eczema drug uptake	31/07/17	RE
Johnson & Johnson : J&J sees sales growth in near-term; raises 2017 profit forecast	18/07/17	RE
Johnson & Johnson : J&J sees sales growth in near-term; raises 2017 profit forecast	18/07/17	RE
Actelion : Johnson & Johnson expects to complete Actelion purchase on June 16	09/06/17	RE
Actelion : Johnson & Johnson expects to complete Actelion purchase on June 16	09/06/17	RE
Actelion : Johnson & Johnson expects to complete of Actelion offer on June 16	09/06/17	RE
Akzo Nobel : Cross-border M&A between U.S. and European firms at 10 year high	22/05/17	RE
Actelion : Johnson & Johnson offers EU concessions over Actelion deal	18/05/17	RE
Actelion : Johnson & Johnson target Actelion could exit Swiss benchmark SMI index this month	20/04/17	RE
Actelion : Johnson & Johnson first quarter revenue misses estimates; new forecast includes Actelion	18/04/17	RE
Actelion : shareholders back R&D spinoff, keep J&J deal on track	05/04/17	RE
Actelion : J&J declares Actelion tender offer a success, sees closing in second quarter	31/03/17	RE
Genmab A/S : and J&J's cancer drug set for blockbuster sales this year	22/02/17	RE
Bristol Myers Squibb : Icahn buys Bristol-Myers shares, adding to activist pressure	21/02/17	RE
Actelion : How Sanofi lost out to J&J in $30 billion battle for Actelion	16/02/17	RE

Analyst Recommendations on Actelion

Dollar's post-Fed rally pauses, U.S. stocks end lower	16/12/16	RE
Actelion : raises guidance for third time this year on strong PAH sales	20/10/16	RE

More recommendations

Press releases Actelion

Actelion : Pharmaceuticals US, Inc, - Results from Expert Delphi Consensus Survey on Treatment of Pulmonary Arterial Hypertension with Oral Prostacyclin Pathway Agents	06/04/20	AQ
Actelion : Cancellation of publicly held Actelion shares and delisting from SIX Swiss Exchange as of November 7, 2017	31/10/17	GL
Actelion : Befreiung von Publizitätspflichten zur Aufrechterhaltung der Kotierung	30/06/17	GL
Actelion : Johnson & Johnson Completes Acquisition of Actelion	16/06/17	GL
Actelion : Publication of Idorsia's prospectus relating to the listing of Idorsia Ltd on SIX Swiss Exchange	15/06/17	PU

More press releases

News in other languages on Actelion

Après Bioverativ, Sanofi s'empare de la biotech belge Ablynx pour 3,9 mrd EUR	29/01/18
Après Bioverativ, Sanofi rachète la biotech belge Ablynx pour 3,9 mrd EUR	29/01/18
Avec Bioverativ, Sanofi devient un leader mondial dans l'hémophilie	22/01/18
GNW-News: Cancellation of publicly held Actelion shares and delisting from SIX Swiss Exchange as of November 7, 2017	31/10/17
Actelion : Cancellation of publicly held Actelion shares and delisting from SIX Swiss Exchange as of November 7, 2017	31/10/17

Company Profile

Sector

Biotechnology & Medical Research

More about the company

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
VERTEX PHARMACEUTICALS INCORPORATED	+15.20%	121B
REGENERON PHARMACEUTICALS, INC.	+19.67%	113B
ARGENX SE	+18.95%	26.02B
BIONTECH SE	-23.86%	19.39B
GENMAB A/S	-19.03%	15.91B
BEIGENE, LTD.	-20.90%	15.09B
WUXI APPTEC CO., LTD.	-46.14%	15.06B
SAREPTA THERAPEUTICS, INC.	+63.85%	14.93B
NEUROCRINE BIOSCIENCES, INC.	+4.49%	13.85B

Bio Therapeutic Drugs

Our Free Content Help you Secure and Increase the Performance of Your Investments

Securing my Investments

fermer